Table 4:
Association between HBV and HDV infection with hepatocellular carcinoma or cirrhosis.
| HBV and HDV status |
HCC vs. Controls† | Cirrhosis without HCC vs. Controls† |
Cirrhosis without HCC vs. HCC‡ |
|---|---|---|---|
| OR (95% CI) | OR (95% CI) | OR (95% CI) | |
| HDV status determined by HDV RNA positivity | |||
| Unadjusted models | |||
| HBsAg− / HDV RNA− | 1.0 (Reference) | 1.0 (Reference) | 1.0 (Reference) |
| HBsAg+ / HDV RNA− | 6.50 (4.67, 9.06) | 5.72 (3.68, 8.89) | 0.88 (0.57, 1.36) |
| HBsAg+ / HDV RNA+ | − (8.59, −) | − (11.49, −) | 1.35 (0.48, 3.85) |
| Adjusted models¶ | |||
| HBsAg− / HDV RNA− | 1.0 (Reference) | 1.0 (Reference) | 1.0 (Reference) |
| HBsAg+ / HDV RNA− | 9.11 (6.09, 13.61) | 7.36 (4.49, 12.07) | 0.64 (0.37, 1.11) |
| HBsAg+ / HDV RNA+ | − | − | 0.70 (0.22, 2.24) |
| HDV status determined by anti-HDV positivity | |||
| Unadjusted models | |||
| HBsAg− / anti-HDV − | 1.0 (Reference) | 1.0 (Reference) | 1.0 (Reference) |
| HBsAg+ / anti-HDV − | 6.40 (4.58, 8.94) | 5.58 (3.57, 8.71) | 0.87 (0.56, 1.35) |
| HBsAg+ / anti-HDV+ | 27.21 (6.23, 118.86) | 33.75 (7.10, 160.49) | 1.24 (0.52, 2.94) |
| Adjusted models¶ | |||
| HBsAg− / anti-HDV− | 1.0 (Reference) | 1.0 (Reference) | 1.0 (Reference) |
| HBsAg+ / anti-HDV− | 9.09 (6.06, 13.63) | 7.22 (4.38, 11.90) | 0.63 (0.36, 1.09) |
| HBsAg+ / anti-HDV+ | 31.25 (6.81, 143.36) | 31.31 (6.32, 155.10) | 0.80 (0.30, 2.14) |
Abbreviations: CI, confidence intervals; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; HDV, hepatitis D virus; OR, odds ratio
−
Cannot be estimated
†
OR estimates derived from polytomous logistic regression model comparing HCC cases and cirrhosis without HCC cases to controls.
‡
OR estimates derived from logistic regression models comparing cirrhosis without HCC cases and HCC cases
¶
Adjusted for age, sex, ethnicity, study site, earth floor, alcohol abuse, cigarette smoking, family history of cancer, HCV antibody, Ser-249 TP53 mutation, and BMI